Hancock Whitney Corp Sells 251 Shares of Cencora, Inc. (NYSE:COR)

Hancock Whitney Corp lowered its holdings in shares of Cencora, Inc. (NYSE:COR) by 0.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,364 shares of the company’s stock after selling 251 shares during the quarter. Hancock Whitney Corp’s holdings in Cencora were worth $16,738,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of COR. New Millennium Group LLC acquired a new stake in Cencora during the 2nd quarter worth approximately $26,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora during the second quarter worth $30,000. Concord Wealth Partners bought a new stake in Cencora in the 3rd quarter valued at $30,000. LRI Investments LLC acquired a new position in Cencora in the 1st quarter worth $31,000. Finally, SYSTM Wealth Solutions LLC bought a new position in Cencora during the 2nd quarter worth about $36,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 15.80% of the stock is owned by company insiders.

Cencora Stock Performance

COR opened at $245.02 on Monday. The business has a 50 day moving average of $233.22 and a 200-day moving average of $231.70. The stock has a market cap of $48.28 billion, a price-to-earnings ratio of 32.63, a PEG ratio of 1.63 and a beta of 0.44. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. Cencora, Inc. has a 12-month low of $195.83 and a 12-month high of $251.56.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.90%. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date is Friday, November 15th. Cencora’s dividend payout ratio is presently 29.29%.

Wall Street Analyst Weigh In

COR has been the subject of several recent research reports. UBS Group upped their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Evercore ISI boosted their price objective on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. lifted their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Finally, Wells Fargo & Company increased their price objective on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $271.20.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.